Should I buy or sell Immutep stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immutep in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMMP shares. View IMMP analyst ratings or view top-rated stocks .

What is Immutep's stock price target for 2024?

1 equities research analysts have issued 1-year target prices for Immutep's stock. Their IMMP share price targets range from $7.00 to $10.00. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 312.6% from the stock's current price. View analysts price targets for IMMP or view top-rated stocks among Wall Street analysts .

How have IMMP shares performed in 2023?

Immutep's stock was trading at $1.75 at the start of the year. Since then, IMMP shares have increased by 17.7% and is now trading at $2.06. View the best growth stocks for 2023 here .

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Nuwellis (CHFS) , MEI Pharma (MEIP) , VBI Vaccines (VBIV) , Vaxart (VXRT) , Amarin (AMRN) , Gilead Sciences (GILD) , Heat Biologics (HTBX) , Inovio Pharmaceuticals (INO) , Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT) .

Who are Immutep's major shareholders?

Immutep's stock is owned by a variety of institutional and retail investors. Top institutional investors include Oracle Investment Management Inc. (0.59%), Meridian Wealth Management LLC (0.35%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Immutep?

Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Immutep (IMMP) Stock Price, News & Analysis

$2.09

+0.01 (+0.48%)

(As of 11:13 AM ET)

Compare

Today's Range: $2.05
▼
$2.10
50-Day Range: $1.76
▼
$2.08
52-Week Range: $1.50
▼
$3.90

Volume: 14,346 shs
Average Volume: 532,747 shs
Market Capitalization: $183.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

Immutep MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 312.6% Upside
$8.50 Price Target
Short Interest: Healthy
0.43% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.42) to ($0.32) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

499th out of 942 stocks

Pharmaceutical Preparations Industry

217th out of 424 stocks

3.5

Analyst's Opinion

Consensus Rating
Immutep has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.50, Immutep has a forecasted upside of 312.6% from its current price of $2.06.
Amount of Analyst Coverage
Immutep has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.43% of the outstanding shares of Immutep have been sold short.
Short Interest Ratio / Days to Cover
Immutep has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Immutep has recently decreased by 7.11%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Immutep does not currently pay a dividend.
Dividend Growth
Immutep does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMMP.

0.0

News and Social Media Coverage

MarketBeat Follows
Only 1 people have added Immutep to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immutep insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.07% of the stock of Immutep is held by insiders.
Percentage Held by Institutions
Only 1.84% of the stock of Immutep is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Immutep are expected to grow in the coming year, from ($0.42) to ($0.32) per share.
Price to Book Value per Share Ratio
Immutep has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Immutep Stock (NASDAQ:IMMP)

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

IMMP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMMP Stock News Headlines

December 2, 2023 | americanbankingnews.com

Immutep (NASDAQ:IMMP) Share Price Crosses Above 50 Day Moving Average of $1.87

November 6, 2023 | finance.yahoo.com

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

December 11, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 3, 2023 | finanznachrichten.de

Immutep Limited: Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

November 3, 2023 | markets.businessinsider.com

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

November 2, 2023 | finance.yahoo.com

Immutep to Participate in November Investor Events

October 27, 2023 | markets.businessinsider.com

Buy Rating for Immutep (IMMP) Supported by Strong Phase 2 Study Results and Solid Financial Position

October 25, 2023 | msn.com

Immutep receives about A$1.13M R&D tax incentive from Australian govt

December 11, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

October 25, 2023 | finance.yahoo.com

Immutep receives ~A$1.13 million R&D Tax Incentive

October 24, 2023 | finance.yahoo.com

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

October 23, 2023 | stockhouse.com

Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

October 22, 2023 | markets.businessinsider.com

Immutep : Efti+ Keytruda Generates Excellent OS Benefit In Phase II Trial In Metastatic NSCLC

October 3, 2023 | finance.yahoo.com

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

September 5, 2023 | finance.yahoo.com

Immutep to Participate in September Investor Conferences

August 30, 2023 | markets.businessinsider.com

Robert W. Baird Reaffirms Their Buy Rating on Immutep (IMMP)

August 3, 2023 | msn.com

Immutep Limited - ADR (IMMP) Price Target Increased by 21.21% to 2.84

August 1, 2023 | finance.yahoo.com

Immutep Receives Positive Scientific Advice from European Medicines Agency

June 20, 2023 | finance.yahoo.com

Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3

June 5, 2023 | benzinga.com

Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting

June 3, 2023 | au.finance.yahoo.com

IMMP - Immutep Limited

June 2, 2023 | finance.yahoo.com

Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer

May 18, 2023 | msn.com

Maxim Group Maintains Buy Rating for Immutep: Here's What You Need To Know

May 18, 2023 | finance.yahoo.com

Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data

May 17, 2023 | msn.com

Immutep Soars with New Cancer Treatment

May 17, 2023 | msn.com

Immutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 Trial

May 16, 2023 | finance.yahoo.com

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

See More Headlines

Receive IMMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/11/2023
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IMMP
CUSIP: N/A
CIK: 1506184
Web: www.immutep.com
Phone: (128) 315-7003
Fax: 61-2-8569-1880
Employees: 2,021
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.50
High Stock Price Target: $10.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +308.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 13.81
Quick Ratio: 13.81

Sales & Book Value

Annual Sales: $3.50 million
Price / Sales: 52.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.04 per share
Price / Book: 2.00

Miscellaneous

Outstanding Shares: 87,930,000
Free Float: 85,231,000
Market Cap: $182.89 million
Optionable: Not Optionable
Beta: 2.21

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Marc Voigt (Age 50)
CEO, MD, CFO, Chief Business Officer & Executive Director
Comp: $367.95k
Ms. Deanne Miller LLB (Age 46)
COO, General Counsel & Joint Company Secretary
Comp: $240.62k
Dr. Frederic Triebel M.D. (Age 68)
Ph.D., Chief Scientific Officer & Executive Director
Comp: $293.73k
Mr. Christian Mueller BBA
MSc., Senior Vice President of Regulatory & Strategy
Mr. Florian D. Vogl M.D.
M.Sc., Ph.D., Chief Medical Officer
Ms. Indira Naidu
Joint Company Secretary

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IMMP Stock Analysis - Frequently Asked Questions

Should I buy or sell Immutep stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immutep in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMMP shares.
View IMMP analyst ratings or view top-rated stocks.
What is Immutep's stock price target for 2024?: 1 equities research analysts have issued 1-year target prices for Immutep's stock. Their IMMP share price targets range from $7.00 to $10.00. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 312.6% from the stock's current price.
View analysts price targets for IMMP or view top-rated stocks among Wall Street analysts.
How have IMMP shares performed in 2023?: Immutep's stock was trading at $1.75 at the start of the year. Since then, IMMP shares have increased by 17.7% and is now trading at $2.06.
View the best growth stocks for 2023 here.
What other stocks do shareholders of Immutep own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Nuwellis (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT).

Who are Immutep's major shareholders?: Immutep's stock is owned by a variety of institutional and retail investors. Top institutional investors include Oracle Investment Management Inc. (0.59%), Meridian Wealth Management LLC (0.35%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of Immutep?: Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IMMP) was last updated on 12/11/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial